The head of the World Health Organization (WHO) cautioned Monday that no “silver bullet” for the coronavirus may emerge from the flurry of potential vaccines entering phase 3 trials. Read More

AbbVie, Amgen and Takeda Pharmaceuticals have launched a joint phase 2 trial aimed at repurposing drugs for use as COVID-19 treatments. Read More

Severely ill COVID-19 patients given Relief Therapeutics’ RLF-100 (aviptadil) experienced rapid recovery in just three days, according to the company and its research partner NeuroRx. Read More

Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities. Read More

Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID), told the House’s coronavirus subcommittee Friday that he’s still “cautiously optimistic” that a COVID-19 vaccine will be delivered before year’s end. Read More

Pfizer and BioNTech have signed an agreement with Japan’s Ministry of Health to supply the country with 120 million doses of their COVID-19 vaccine. Read More

Merck said it plans to launch two large phase 3 trials of its oral COVID-19 antiviral candidate MK-4482 in September and is also moving ahead with trials of two potential vaccines. Read More

Sanofi and GlaxoSmithKline (GSK) have secured a $2.1 billion U.S. government contract to develop and produce 100 million doses of their COVID-19 vaccine candidate. Read More